DeepMed Research

JAZZ PHARMACEUTICALS FRANCE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2003-01-01

Employees: -

Market Cap: -

Website: https://www.jazzpharma.com/careers/open-positions/

Clinical Trials

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Phase 3

Terminated

Conditions: RTT
Rett Syndrome

Interventions: Drug: GWP42003-P
Drug: Placebo

First Posted Date: 2019-02-21

Last Posted Date: 2022-09-02

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT03848832

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder

Phase 2

Terminated

Conditions: Autism Spectrum Disorder

Interventions: Drug: GWP42006

First Posted Date: 2019-02-21

Last Posted Date: 2022-09-02

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03849456

Locations: 🇺🇸
Clinical Trial Site, Columbus, Ohio, United States

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hematologic Malignancy
Acute Lymphocytic Leukemia
Myelodysplastic Syndromes

Interventions: Drug: CPX-351

First Posted Date: 2018-06-14

Last Posted Date: 2021-07-22

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT03555955

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 10 locations

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Phase 3

Completed

Conditions: Idiopathic Hypersomnia

Interventions: Drug: JZP-258
Drug: Placebo Oral Solution

First Posted Date: 2018-05-22

Last Posted Date: 2021-11-24

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 154

Registration Number: NCT03533114

Locations: 🇺🇸
PAB Clinical Research, Brandon, Florida, United States
🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇺🇸
Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States

and more 60 locations

A Post-Marketing Observational Study of VYXEOS™

Completed

Conditions: Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Therapy-Related Acute Myeloid Leukemia

Interventions: Drug: CPX-351

First Posted Date: 2018-05-16

Last Posted Date: 2020-08-05

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT03526926

Locations: 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸
Tulane University Hospital & Clinic, New Orleans, Louisiana, United States
🇺🇸
Franciscan Physician Network Oncology and Hematology Specialists, Indianapolis, Indiana, United States

and more 4 locations

A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease

Phase 2

Withdrawn

Conditions: Parkinson's Disease
Tremor

Interventions: Drug: Placebo
Drug: CX-8998

First Posted Date: 2018-02-19

Last Posted Date: 2021-05-28

Lead Sponsor: Jazz Pharmaceuticals

Registration Number: NCT03436953

CX-8998 for Absence Seizures

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: CX-8998

First Posted Date: 2018-01-23

Last Posted Date: 2022-09-08

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT03406702

Locations: 🇺🇸
Arkansas Epilepsy Program, Little Rock, Arkansas, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
NYU Comprehensive Epilepsy Center, New York, New York, United States

and more 4 locations

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Phase 2

Completed

Conditions: Graft-versus-host Disease
Acute-graft-versus-host Disease

Interventions: Drug: Defibrotide
Drug: Standard of Care

First Posted Date: 2017-11-13

Last Posted Date: 2021-08-18

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 152

Registration Number: NCT03339297

Locations: 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇭🇷
Klinichki Bolnicki Centar Zagreb, Zagreb, Croatia
🇩🇪
Uniklinik Köln, Köln, Germany

and more 59 locations

A Phase 2 RCT Study of CX-8998 for Essential Tremor

Phase 2

Completed

Conditions: Essential Tremor

Interventions: Drug: CX-8998
Drug: Placebo

First Posted Date: 2017-04-05

Last Posted Date: 2021-11-23

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT03101241

Locations: 🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States
🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸
St. Louis Clinical Trials, Saint Louis, Missouri, United States

and more 19 locations

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Phase 2

Completed

Conditions: Excessive Sleepiness
Parkinson Disease

Interventions: Other: Placebo
Drug: JZP-110

First Posted Date: 2017-01-31

Last Posted Date: 2020-01-09

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT03037203

Locations: 🇺🇸
Bioclinica Research, Orlando, Florida, United States
🇺🇸
PAB Clinical Research, Brandon, Florida, United States
🇺🇸
MD Clinical, Hallandale Beach, Florida, United States

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy